Granted Fifth Patent for J-Plasma™;
Presenting at the 41st Annual AAGL Conference
MELVILLE, N.Y. -- (Business Wire)
Bovie Medical Corporation (the “Company”) (NYSE MKT: BVX), a
manufacturer and marketer of electrosurgical products, today announced
that the Company has received initial orders for J-Plasma™ and has been
granted its fifth patent for the product. The Company has five
additional patents pending based on the J-Plasma™ technology.
In other news, the Company will be attending and presenting J-Plasma™ at
the 41st AAGL Global Congress on minimally invasive
gynecology November 5-9th in Las Vegas, Nevada. The AAGL
conference is attended annually by over 3,000 gynecologists from
throughout the world.
J-Plasma™ is formed by passing helium over Bovie’s proprietary
electrode, which is held at high voltage and high frequency, producing a
luminous discharge beam. The electrode can also be in the form of a
retractable surgical blade, providing multiple modes of operation in a
single instrument. The extended surgical blade can be used for incisions
and other cutting procedures, and when retracted, the blade is used to
form the J-Plasma beam for coagulation. The extended blade can also be
used in combination with the J-Plasma beam, providing an enhanced
cutting capability with minimal impact on surrounding tissue.
Cautionary Note on Forward-Looking Statements
Certain matters discussed in this news release and oral statements made
from time to time by representatives of the Company may constitute
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995 and the Federal securities laws. Although
the Company believes that the expectations reflected in such
forward-looking statements are based upon reasonable assumptions, it can
give no assurance that its expectations will be achieved.
Forward-looking information is subject to certain risks, trends and
uncertainties that could cause actual results to differ materially from
those projected. Many of these factors are beyond the Company’s ability
to control or predict. Important factors that may cause actual results
to differ materially and that could impact the Company and the
statements contained in this news release can be found in the Company’s
filings with the Securities and Exchange Commission including the
Company’s Report on Form 10-K for the year ended December 31, 2011. For
forward-looking statements in this new release, the Company claims the
protection of the safe harbor for forward-looking statements contained
in the Private Securities Litigation Reform Act of 1995. The Company
assumes no obligation to update or supplement any forward-looking
statements whether as a result of new information, future events or
For further information about the Company’s current and new products,
please refer to the Investor Relations section of Bovie’s website www.boviemed.com.
Buttonwood Advisory Group, Inc.
Source: Bovie Medical Corporation
© 2017 Canjex Publishing Ltd. All rights reserved.